ECOG-ACRIN Active Clinical Trials

Numerous clinical trials are always active (ie, open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. The buttons below depict the general research categories being investigated in ECOG-ACRIN clinical trials. To access information within a particular category, click on the relevant button. Upon clicking, the color of the button will change from grey to red, and a table will appear on screen. The table will display the study number, study description, lead investigator(s), accrual goal, and the date participating institutions started to open the trial. Please read the ECOG-ACRIN Disclaimer in its entirety before accessing this information.

Need More Information About a Particular Clinical Trial? Contact Us

To view educational materials, click on the links provided in the Educational Materials column. To send an email to the study chair, click on their name and a new email window will open.

Brain

Breast

Cancer Care Delivery Research

Cancer Control and Survivorship

Trials Currently Recruiting Participants - Head and Neck Cancer Committee

STUDY	DESCRIPTION	ECOG-ACRIN STUDY CHAIR (STATISTICIAN)	ACCRUAL GOAL	DATE ACTIVATED	EDUCATIONAL MATERIALS
EA3132	Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck	Robert L. Ferris, MD, PhD, Chair Christine H. Chung, MD, Co-Chair (Shuli Li, PhD)	345	03/29/2016	EA3132 Resources
EA3161	A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV-Positive Oropharyngeal Cancer	Nabil F. Saba, MD, Chair Christine H. Chung, MD, Translational Science Co-Chair (Shuli Li, PhD)	744	06/20/2019	EA3161 Resources
EA3163	Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-operative Radiation versus Surgery and Post-operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma	Nabil F. Saba, MD, FACP, Chair Derrick Lin, MD, Co-Chair (Shuli Li, PhD)	82	03/28/2018	EA3163 Resources
EA3191	A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features	Dan P. Zandberg, MD, Chair (Yael Flamand, MS)	282	01/08/2021	EA3191 Resources

STUDY DESCRIPTION ECOG-ACRIN STUDY CHAIR
(STATISTICIAN) ACCRUAL
GOAL DATE
ACTIVATED EDUCATIONAL
MATERIALS

EA3132 Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck Robert L. Ferris, MD, PhD, Chair
Christine H. Chung, MD, Co-Chair
(Shuli Li, PhD) 345 03/29/2016 EA3132 Resources

EA3161 A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV-Positive Oropharyngeal Cancer Nabil F. Saba, MD, Chair
Christine H. Chung, MD, Translational Science Co-Chair
(Shuli Li, PhD)
744 06/20/2019 EA3161 Resources

EA3163 Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-operative Radiation versus Surgery and Post-operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma Nabil F. Saba, MD, FACP, Chair
Derrick Lin, MD, Co-Chair
(Shuli Li, PhD) 82 03/28/2018 EA3163 Resources

EA3191 A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Dan P. Zandberg, MD, Chair
(Yael Flamand, MS) 282 01/08/2021 EA3191 Resources

Download

Head and Neck Cancer Active Clinical Trials

Need More Information About a Particular Clinical Trial? Contact Us

Trials Currently Recruiting Participants - Head and Neck Cancer Committee